ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ARQT Arcutis Biotherapeutics Inc

8.31
-0.28 (-3.26%)
2024年4月27日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Arcutis Biotherapeutics Inc ARQT NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.28 -3.26% 8.31 08:46:45
始値 安値 高値 終値 前日終値
8.59 8.36 8.85 8.47 8.59
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/1021:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
2024/4/0605:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
2024/4/0120:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
2024/3/2821:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
2024/3/1121:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
2024/3/1105:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
2024/3/1006:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
2024/3/0707:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0707:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0707:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0606:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
2024/3/0507:47EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0507:42EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0507:40EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0506:10EDGAR2Form 8-K - Current report
2024/3/0506:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
2024/3/0422:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
2024/3/0206:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0206:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/3/0107:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
2024/2/2913:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
2024/2/2906:54EDGAR2Form 144 - Report of proposed sale of securities
2024/2/2906:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/2/2906:10EDGAR2Form 8-K - Current report
2024/2/2906:10GLOBEArcutis Announces Proposed Public Offering
2024/2/2906:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
2024/2/2806:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
2024/2/2721:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/2721:44EDGAR2Form 8-K - Current report
2024/2/2719:50GLOBEArcutis Announces Fourth Quarter and Full Year 2023..
2024/2/1622:00GLOBEArcutis to Report Fourth Quarter and Full Year 2023..
2024/2/1608:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1608:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1608:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1606:20EDGAR2Form 8-K - Current report
2024/2/1606:19EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
2024/2/1323:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/0914:15EDGAR2Form EFFECT - Notice of Effectiveness
2024/2/0906:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/2/0706:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
2024/2/0107:22EDGAR2Form S-3 - Registration statement under Securities Act of..
2024/1/3122:00GLOBEArcutis to Present at the Guggenheim Healthcare Talks – 6th..
2024/1/2922:00GLOBEJournal of the American Academy of Dermatology Publishes..
2024/1/2506:02EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
2024/1/2222:00GLOBEZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment..
2024/1/1806:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1806:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1806:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1806:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1418:00GLOBEMajority of Individuals with Atopic Dermatitis Improved with..

最近閲覧した銘柄

Delayed Upgrade Clock